Stopping empirical antifungal therapy early based on a predefined set of criteria in children with high risk febrile neutropenia is safe: a randomized feasibility trial
Not Applicable
- Conditions
- Health Condition 1: B49- Unspecified mycosis
- Registration Number
- CTRI/2021/02/031563
- Lead Sponsor
- All India Institute of Medical Sciences New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Having high risk febrile neutropenia and being started on empirical anti-fungals
Exclusion Criteria
1.Treatment with therapeutic antifungal in the preceding 14 days
2.Residence >1 hour of reach from the hospital
3.Non-availability of reliable and compliant caretaker
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Breakthrough fungal infectionTimepoint: 28 days from randomisation
- Secondary Outcome Measures
Name Time Method All cause mortalityTimepoint: 28 days from randomisation;Antifungal free daysTimepoint: 28 days from randomisation;Rehospitalization rateTimepoint: 28 days from randomisation